[Endocrine paraneoplastic syndromes]
- PMID: 29387897
- DOI: 10.1007/s00108-017-0377-y
[Endocrine paraneoplastic syndromes]
Erratum in
-
[Correction to: Endocrine paraneoplastic syndromes].Internist (Berl). 2018 May;59(5):438. doi: 10.1007/s00108-018-0413-6. Internist (Berl). 2018. PMID: 29594437 German. No abstract available.
Abstract
Endocrine paraneoplastic syndromes result from the production of bioactive substances from neoplastic cells, of endocrine or neuroendocrine origin. Typically these are located in the lungs, the gastrointestinal tract, pancreas, thyroid gland, adrenal medulla, skin, prostate or breast. In endocrine paraneoplastic syndromes the secretion of peptides, amines or other bioactive substances is always ectopic and not related to the anatomical source. The clinical presentation, however, is indistinguishable from a suspected eutopic endocrine tumor posing a diagnostic challenge. The most common endocrine paraneoplastic syndromes are based on the secretion of antidiuretic hormone (ADH) resulting in hyponatremia, secretion of adrenocorticotropic hormone (ACTH) or rarely corticotropin-releasing hormone (CRH) resulting in Cushing syndrome as well as secretion of growth hormone-releasing hormone resulting in acromegaly. Paraneoplastic endocrine syndromes mainly occur in highly malignant tumors; however, the development of these tumors does not necessarily correlate with tumor stage, malignant potential or prognosis. As endocrine paraneoplastic syndromes are a rare complication, there are hardly any evidence-based therapeutic recommendations. Treatment of the underlying tumor is the first choice and in a palliative setting symptomatic therapy is possible.
Keywords: Acromegaly; Cushing syndrome; Hormones, ectopic; Inappropriate ADH syndrome; Positron emission tomography computed tomography.
Similar articles
-
[CME: Paraneoplastic Endocrine Syndromes].Praxis (Bern 1994). 2018 Nov;107(24):1309-1315. doi: 10.1024/1661-8157/a003132. Praxis (Bern 1994). 2018. PMID: 30482117 Review. German.
-
[Ectopic hormone secretion by neuroendocrine tumors].Internist (Berl). 2012 Feb;53(2):145-51. doi: 10.1007/s00108-011-2920-6. Internist (Berl). 2012. PMID: 22290319 German.
-
[Paraneoplastic endocrine syndromes: diagnosis and management].Rev Med Suisse. 2009 Aug 26;5(214):1668-74. Rev Med Suisse. 2009. PMID: 19772199 Review. French.
-
[Paraneoplastic hormonal syndromes].An Sist Sanit Navar. 2005 May-Aug;28(2):213-26. doi: 10.4321/s1137-66272005000300006. An Sist Sanit Navar. 2005. PMID: 16155618 Review. Spanish.
-
Paraneoplastic endocrine syndromes: a contemporary overview.Expert Rev Endocrinol Metab. 2025 Jan;20(1):51-62. doi: 10.1080/17446651.2024.2448782. Epub 2025 Jan 5. Expert Rev Endocrinol Metab. 2025. PMID: 39757400 Review.
Cited by
-
[Diagnostics and treatment of clinically relevant paraneoplastic syndromes].Schmerz. 2022 Dec;36(6):447-457. doi: 10.1007/s00482-022-00669-3. Epub 2022 Oct 19. Schmerz. 2022. PMID: 36260170 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials